On Tuesday, Centene Corporation (NYSE:CNC) reported fourth-quarter sales of $40.80 billion. That’s up 3.41% year-over-year, beating the consensus of $39.13 billion.
Centene earned an adjusted EPS of 80 cents during the quarter, beating the consensus of 49 cents. For the fourth quarter of 2024, premium and service revenues increased 3% to $36.3 billion from $35.3 billion in the comparable period of 2023.
A health benefits ratio (HBR) of 89.6% for the fourth quarter of 2024 represents an increase from 89.5% in the comparable period in 2023. The increase was primarily driven by higher acuity in Medicaid, which resulted from the redetermination process.
The company also saw Membership increases of 12% in Marketplace and 50% in Medicare PDP, compared to the fourth quarter of 2023.
Also Read: RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
“Despite a year of unprecedented industry headwinds, Centene demonstrated significant operational improvements, strengthened our talent bench, and delivered on our financial commitments in 2024,” said CEO Sarah London.
Centene reported 28.6 million members as of December 31, up from 27.5 million in 2023.
Enrollment in its Medicaid plans dipped as redeterminations completed, from 14.5 million to 13 million. Marketplace coverage increased year over year, growing from 3.9 million to 4.4 million.
Guidance: Centene said it will raise its premium and service revenue guidance window by $4 billion. The company now expects to bring in between $158 billion and $160 billion for 2025.
In December, the company outlined 2025 guidance with premium and service revenues of $154 billion to $156 billion. The company expects total revenue between $166.5 billion and $169.5 billion.
Centene reaffirms FY2025 adjusted EPS of greater than $7.25 compared to consensus of $7.22.
Price Action: Centene stock is down 5.13% at $61.50 at last check Tuesday.
Read Next:
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。